53
Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Embed Size (px)

Citation preview

Page 1: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Mark Pletcher6/10/2011

Quantifying Treatment Effects

Page 2: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Rationale

Any treatment involves tradeoffs Weigh benefits against risks/costs

Benefit$$ Harm

Page 3: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Rationale

Sometimes the decision is difficult!

Benefit $$ Harm

Page 4: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Rationale

Benefit $$ Harm

How big is this box?

And this one?

Page 5: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Rationale

Tests can help us understand who is most likely to benefit from a treatment

Benefit $$ Harm

How big is this box?

And this one?

Page 6: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Rationale

Tests can help us understand who is most likely to benefit from a treatment Rapid strep to decide who will benefit

from penicillin BNP to decide who will benefit from

furosemide CRP to decide who will benefit from

statins

Page 7: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Rationale

The utility of a test depends on:

How beneficial the treatment is How harmful the treatment is How much the test tells us about

these benefits and harms in a given individual

Risk of harm from the test itself

Page 8: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Rationale

The utility of a test depends on:

How beneficial the treatment is How harmful the treatment is How much the test tells us about

these benefits and harms in a given individual

Risk of harm from the test itselfThe topic for this lecture

Page 9: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Outline

Is an intervention really beneficial? How beneficial is it? Pitfalls Examples

Page 10: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Is the intervention beneficial?

Randomized trials compare an outcome in treated to untreated persons MI in 10% vs. 15% Duration of flu symptoms 3 vs. 5 days

Page 11: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Is the intervention beneficial?

Randomized trials compare an outcome in treated to untreated persons MI in 10% vs. 15% Duration of flu symptoms 3 vs. 5 days

*Statistics* are used to decide if should reject the “null hypothesis” and accept that the intervention is beneficial

Page 12: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Is the intervention beneficial?

But statistics cannot help us interpret effect size

Page 13: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit Effect size

How do we summarize and communicate this?

What is really important for clinicians and policymakers?

Page 14: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit Effect size

How do we summarize and communicate this?

What is really important for clinicians and policymakers?

Example: MI in 10% vs. 15% Q: What do we do with these two

numbers?

Page 15: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

Two simple possibilities:

10% / 15% = 0.66 15% - 10% = 5%

Page 16: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

Two simple possibilities:

10% / 15% = 0.66 15% - 10% = 5%

Relative Risk (RR)

Absolute Risk Reduction (ARR)

Page 17: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

Relative risk as a measure of effect size

RR = 0.66 – is this big or small?

Page 18: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

Relative risk as a measure of effect size

RR = 0.66 – is this big or small? MI: 10% vs. 15% in

10 years Death: 50% vs. 75% in 3 years Basal Cell CA: 2% vs. 3% in lifetime

Page 19: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

Relative risk as a measure of effect size

RR = 0.66 – is this big or small? MI: 10% vs. 15% in

10 years Death: 50% vs. 75% in 3 years Basal Cell CA: 2% vs. 3% in lifetime

Medium

Big

Small

Page 20: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

Relative risk as a measure of effect size

RR = 0.66 – is this big or small? MI: 10% vs. 15% in 10 years Death: 50% vs. 75% in 3 years Basal Cell CA: 2% vs. 3% in lifetime

RR is NOT the best measure of effect size

Page 21: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

Absolute risk reduction (ARR) is better

ARR = Risk difference = Risk2 – Risk1

Page 22: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

Absolute risk reduction (ARR) is better

RR ARRMI: 10% vs. 15% in 10 years .66

5%Death: 50% vs. 75% in 3 years .66 25%

Basal Cell CA: 2% vs. 3% in lifetime .66 1%

Page 23: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Q: What does the 34% reduction mean?

Page 24: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Nimotop® Ad Graph

22% 33%

Risk1 = 61/278 = 21.8% Risk2 = 92/276 = 33% RR = 22%/33% = .66 ARR = 33% - 22% = 11%

Page 25: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Nimotop® Ad Graph

22% 33%

Risk1 = 61/278 = 21.8% Risk2 = 92/276 = 33% RR = 22%/33% = .66 ARR = 33% - 22% = 11%

What is 34%?

Page 26: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Nimotop® Ad Graph

22% 33%

Risk1 = 61/278 = 21.8% Risk2 = 92/276 = 33% RR = 22%/33% = .66 ARR = 33% - 22% = 11%

Relative risk reduction (RRR) =

1 – RR = 1-.66 = .34 or 34%

Page 27: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

RRR is no better than RR

RR RRRMI: 10% vs. 15% in 10 years .66

34%Death: 50% vs. 75% in 3 years .66 34%

Basal Cell CA: 2% vs. 3% in lifetime .66 34%

Page 28: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

RRR is ALWAYS bigger than ARR (unless untreated risk is 100%)

Page 29: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

BEWARE of risk reduction language!!

ARR or RRR? “We reduced risk by 34%” “Risk was 34% lower”

Page 30: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

BEWARE of risk reduction language!!

ARR or RRR? “We reduced risk by 34%” can’t tell “Risk was 34% lower” can’t tell

Very hard to be unambiguous!

Page 31: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

Another reason that ARR is better:

Translate it into “Number Needed to Treat”

NNT = 1/ARR

Page 32: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Why is NNT = 1/ARR?

67 no stroke anyway

22 strokes with Nimotop®

11 strokes prevented

22 strokes with with treatment

33 strokes with no treatment

100 SAH patients treated

R2

R1

Page 33: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Why is NNT 1/ARR?

Treat 100 SAH patients prevent 11 strokes

Ratio manipulation:

100 treated 1 treated 9.1 treated11 prevented .11 prevented 1

prevented

= =

Page 34: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Why is NNT 1/ARR?

Treat 100 SAH patients prevent 11 strokes

Ratio manipulation:

100 treated 1 treated 9.1 treated11 prevented .11 prevented 1

prevented

= =

1/ARR = NNT

Page 35: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Why is NNT 1/ARR?

NNT best expressed in a sentence:

“Need to treat 9.1 persons with SAH using nimodipine to prevent 1 cerebral infarction”

Page 36: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

NNT calculation practice

RR ARR NNT?

MI: 10% vs. 15% in 10 years .665%

Death: 50% vs. 75% in 3 years .66 25%

Basal Cell CA: 2% vs. 3% in lifetime .66 1%

Page 37: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

NNT calculation practice

RR ARR NNT?

MI: 10% vs. 15% in 10 years .665% 20

Death: 50% vs. 75% in 3 years .66 25% Basal Cell CA: 2% vs. 3% in lifetime .66 1%

Page 38: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

NNT calculation practice

RR ARR NNT?

MI: 10% vs. 15% in 10 years .665% 20

Death: 50% vs. 75% in 3 years .66 25% 4

Basal Cell CA: 2% vs. 3% in lifetime .66 1%

Page 39: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

NNT calculation practice

RR ARR NNT?

MI: 10% vs. 15% in 10 years .665% 20

Death: 50% vs. 75% in 3 years .66 25% 4

Basal Cell CA: 2% vs. 3% in lifetime .66 1% 100

Page 40: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

NNT expression practice

RR ARR NNT?

MI: 10% vs. 15% in 10 years .665% 20

Death: 50% vs. 75% in 3 years .66 25% 4

Basal Cell CA: 2% vs. 3% in lifetime .66 1% 100

Statins

Chemo

Sunscreen every day

Page 41: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Quantifying the Benefit

NNT expression practice

“Need to treat 20 patients with statins for 10 years to prevent 1 MI”

“Need to treat 4 patients with chemo for 3 years to prevent 1 death”

“Need to treat 100 patients with sunscreen every day for their whole life to prevent 1 basal cell”

Page 42: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Example 1

Randomized controlled trial of the effects of hip replacement vs. screws on re-operation in elderly patients with displaced hip fractures.

Parker MH et al. Bone Joint Surg Br. 84(8):1150-1155.

Page 43: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Example 1Re-

operationNo Re-

operation

Hip Replacement 12 217 229

Internal Fixation with Screws 90 136 226

Parker MH et al. Bone Joint Surg Br. 84(8):1150-1155.

Page 44: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Example 1Re-

operationNo Re-

operation Risk

Hip Replacement 12 217 229

12/229 = 5.2%

Internal Fixation with Screws 90 136 226

90/226 =

39.8%

Page 45: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Example 1Re-

operationNo Re-

operation Risk

Hip Replacement 12 217 229

12/229 = 5.2%

Internal Fixation with Screws 90 136 226

90/226 =

39.8%

RR = R1/R2 = 5.2% / 39.8% = .13

RRR = 1-RR = 1-.13 = 87%

ARR = R2 – R1 = 39.8% - 5.2% = 34.6%

NNT = 1/ARR = 1/.346= 3

“Need to treat 3 patients with hip replacement instead of screws to prevent 1 from needing a re-do operation”

Page 46: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Example 2

JUPITER: Randomized controlled trial of high dose rosuvastatin in patients with LDL<130 and CRP>2.0

Ridker et al. NEJM 2008; 359:2195-207

Page 47: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Example 2

Ridker et al. NEJM 2008; 359:2195-207

Page 48: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Example 2

Ridker et al. NEJM 2008; 359:2195-207

Page 49: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Example 2

HR = (R1/R2) (from regression) = .56

RRR = 1-HR = 1-.56 = 44%

ARR = R2 – R1 = 1.36 - 0.77 = .59 / 100py*

= .0059 / py

NNT = 1/ARR = 1/.0059 = 100/.59 = 169 pys

“Need to treat 169 patients for a year to prevent 1 CVD event”

Or better:

“Need to treat 85 patients for 2 years to prevent 1 CVD event”

(average treatment duration in trial was 1.9 years)

* py = person-years

Page 50: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Example 4

Warfarin vs. placebo for atrial fibrillation

Warfarin Placebo

Risk of major bleed (/yr) 1.2% 0.7%

Ann Intern Med 1999; 131:492-501

Page 51: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Example 4

Warfarin vs. placebo for atrial fibrillation

RR = R1/R2 = 1.2% / .7% = 1.7

RR (flipped) = R2/R1 = .7% / 1.2% = .59

RRR (flipped) = 1-RR = 1 - .59 = 41%

ARR = R2 – R1 = .7% - 1.2% = -.5%

“ARI” – Absolute risk increase = 0.5%

NNT = 1/ARR = 1/-.5% = -200

“NNH” – Number needed to harm = -NNT = 1/ARI = 200

“If you treat 200 Afib patients with warfarin, you will cause 1 major bleed”

Page 52: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Circling back to test utility… Tests help determine:

If the RR applies Treatment for a disease doesn’t help if you don’t

have the disease! Interactions (RR is higher or lower than average)

Statins more effective if CRP is high? Patients with gene XYZ more likely to have a side

effect

Baseline risk The higher the risk, the larger the ARR, the

smaller the NNT

Page 53: Mark Pletcher 6/10/2011 Quantifying Treatment Effects

Key Concepts Test utility depends on how good the

treatment is RR and p-values good for hypothesis

testing/statistics ARR and NNT (and NNH) better for

interpreting clinical importance ARR = risk difference NNT = 1/NNT

Beware RRR and ambiguous language